Diamyd Medical develops precision medicine therapies for the prevention and treatment of autoimmune diabetes.

The investigational flagship product Diamyd^® is a disease-modifying antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and has been granted Fast Track designation by the U.S. FDA. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the U.S.

Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.